Cathepsin V (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin V (CTSV/O60911), HEK293-expressed cysteine protease. Suited for substrate cleavage assays, inhibitor IC50 determination, and antibody validation as a defined positive control.
Expression system
HEK293
Cat. #
REC-CathepsinV

In stock

SKU
REC-CathepsinV
$498.00

Target Overview

Cathepsin V (gene: CTSV; UniProt O60911) is a lysosomal cysteine protease of the papain superfamily, also catalogued under the names Cathepsin L2 and Cathepsin U. The mature protein derives from a 334-amino-acid precursor that undergoes signal-peptide removal and propeptide processing to yield the active, two-chain form characteristic of lysosomal cathepsins. This recombinant is produced in HEK293 cells, providing mammalian glycosylation and folding conditions that support native-like conformation and enzymatic competence — features that are particularly relevant when the protein is used as a substrate-cleavage enzyme or as a structurally faithful antigen for antibody validation. In the laboratory, this recombinant finds utility across several in-vitro formats. For enzymatic characterisation, it can be assayed against fluorogenic peptide substrates (e.g., Z-Phe-Arg-AMC) under mildly acidic conditions that reflect the lysosomal compartment. For inhibitor profiling, the preparation supports IC50 determination against small-molecule cysteine-protease inhibitors, enabling selectivity comparisons within the cathepsin family. As a defined, sequence-verified protein of known origin, it also serves as a reliable positive control in Western blot and immunohistochemistry validation workflows. Researchers seeking to validate antibody performance against CTSV can pair this recombinant with the Triple Point Biologics matched antibody (SKU: RP-CathepsinV), which has been validated for Western blot against human targets. Additionally, the recombinant is amenable to biophysical characterisation by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) for binding-partner studies. Substrate identification experiments by mass spectrometry represent another documented application, given the enzyme's broad specificity toward hydrophobic residues at the P2 position.

Background

Cathepsin V (CTSV; UniProt O60911) is one of the most potent elastolytic cysteine proteases in the human lysosomal compartment, displaying activity toward collagen, elastin, and a range of synthetic fluorogenic substrates. Its expression profile is notably more restricted than that of the closely related Cathepsin L, with high-level transcript and protein detected in thymus, testis, and corneal epithelium, and more limited expression in most other tissues under homeostatic conditions. This expression pattern has led investigators to explore a functional role for Cathepsin V in thymic epithelial antigen processing and corneal physiology. Because lysosomal protease activity is tightly coupled to cell death pathways — including lysosomal membrane permeabilisation and cathepsin-dependent apoptosis — CTSV has been incorporated into multi-gene transcriptomic analyses of cancer biology. Cheng et al. (2026) applied single-cell RNA sequencing and machine-learning approaches to characterise lysosome-mediated cell death in cervical cancer, identifying CTSV among a panel of lysosome-associated genes evaluated as candidate prognostic biomarkers in that tumour type (PMID 42255486). Independently, CTSV has appeared in bioinformatics-driven studies of bladder cancer and endometrial cancer gene signatures, reflecting broader interest in lysosomal protease dysregulation as a research theme across epithelial malignancies. In basic mechanistic research, CTSV is studied as an intracellular protease capable of processing MHC class II-associated invariant chain in thymic antigen-presenting cells, a function with implications for understanding central tolerance. Its structural similarity to Cathepsin L — the active sites differ by only a small number of residues — has made selectivity profiling a methodologically significant challenge, and recombinant CTSV preparations are routinely employed to benchmark inhibitor selectivity across the cathepsin family. For antibody-based detection methods, expression of recombinant CTSV in a mammalian system (HEK293) ensures that post-translational modifications relevant to antibody-epitope recognition are preserved, making this preparation well suited for use as a Western blot loading standard or IHC titration control. Researchers validating anti-CTSV antibodies for tissue-section work are encouraged to run this recombinant alongside the Triple Point Biologics matched antibody (SKU: RP-CathepsinV), which has been validated for Western blot against human CTSV. Triple Point Biologics has produced proteinase and inhibitor antibody reagents since 1994, and this recombinant is formulated to be compatible with those established validation workflows.

Applications

  • Fluorogenic peptide substrate cleavage assay (e.g., Z-Phe-Arg-AMC) under acidic lysosomal buffer conditions
  • Small-molecule cysteine protease inhibitor IC50 determination and cathepsin-family selectivity profiling
  • Antibody validation positive control for Western blot using the matched Triple Point Biologics antibody (SKU: RP-CathepsinV)
  • Substrate identification by mass spectrometry to define CTSV cleavage-site specificity
  • Biophysical binding characterisation by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC)
  • Recombinant antigen standard for ELISA calibration and sensitivity benchmarking
  • Structure-activity relationship (SAR) support in fragment-based or covalent inhibitor discovery campaigns targeting cysteine proteases

References

  1. Cheng Y et al. Single Cell and Machine Learning-Based Analysis of Lysosome Mediated Cell Death Reveals Novel Prognostic Biomarkers and Therapeutic Targets in Cervical Cancer. Int J Genomics. 2026. doi:10.1155/ijog/8487184. PMID: 42255486.
  2. Liu Y et al. Exploring the underlying mechanisms of Hedyotis diffusa and Scutellaria Barbata herb pair on the prognosis and treatment efficacy of bladder cancer patients: an integrated approach of network pharmacology and bioinformatics analysis. BMC Complement Med Ther. 2026. doi:10.1186/s12906-026-05279-5. PMID: 41689016.
  3. Lu S et al. Establishment of insulin resistance-related ten-gene signature in endometrial cancer and identification of ACTL8 as a prognostic and immunological biomarker. Clin Transl Oncol. 2026. doi:10.1007/s12094-026-04230-x. PMID: 41670819.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight does recombinant Cathepsin V run at on SDS-PAGE or Western blot?

The Cathepsin V precursor (334 aa, UniProt O60911) has a predicted mass of ~37 kDa, but the mature two-chain active form — generated after signal-peptide removal and propeptide cleavage — typically resolves as a heavy chain of ~24 kDa and a light chain of ~5 kDa under reducing conditions. On non-reducing SDS-PAGE the two chains may remain disulfide-linked and migrate together near 29 kDa. HEK293-derived glycosylation can add 2–4 kDa, so expect the heavy chain band between 24–28 kDa depending on gel percentage and reducing conditions.

What is the difference between Cathepsin V, Cathepsin L2, and Cathepsin U — is this the same protein?

Yes, all three names refer to the same gene product (CTSV, UniProt O60911). Cathepsin L2 and Cathepsin U are historical synonyms that appeared in the literature before systematic nomenclature was standardised. Cathepsin V is the current recommended name. It is a distinct paralogue from Cathepsin L (CTSL), sharing ~75% amino acid identity but with a notably restricted tissue expression pattern — predominantly thymus, testis, and corneal epithelium — and a slightly narrower substrate preference profile. When searching inhibitor or substrate literature, cross-checking all three names is advisable to avoid missing relevant data.

What fluorogenic substrate and assay buffer should I use to measure recombinant Cathepsin V activity?

Z-Phe-Arg-AMC is the most widely used fluorogenic substrate for Cathepsin V and gives robust signal at substrate concentrations of 10–50 µM. Assay buffer should reflect the lysosomal compartment: 100 mM sodium acetate or sodium phosphate, pH 5.0–5.5, supplemented with 2–5 mM DTT or 5 mM TCEP to maintain the active-site cysteine in a reduced state, and 1 mM EDTA to chelate inhibitory metal ions. Pre-activate the enzyme in assay buffer for 10–15 minutes at 37 °C before adding substrate. Monitor fluorescence at Ex/Em 380/460 nm.

What starting concentration of recombinant Cathepsin V should I use for an in-vitro activity or inhibitor assay?

For a kinetic activity assay with Z-Phe-Arg-AMC, 1–10 nM recombinant Cathepsin V is typically sufficient to generate a linear, measurable fluorescence signal over 30–60 minutes. For inhibitor IC50 determination, keep enzyme concentration at or below the anticipated Ki of your compound to avoid tight-binding artefacts — 1–5 nM is a practical starting point. If you are titrating a covalent or irreversible inhibitor, a pre-incubation step (30 min, room temperature) before substrate addition helps distinguish true IC50 from inactivation rate. Confirm linearity with a no-inhibitor control in each run.

How does pH affect Cathepsin V activity and should I adjust the assay buffer for different experimental contexts?

Cathepsin V is a lysosomal cysteine protease with a pH optimum typically between 5.0 and 6.0 for most peptide substrates. Activity drops sharply above pH 6.5 and is essentially negligible at neutral or alkaline pH. If you are modelling extracellular tumour microenvironment proteolysis (pH ~6.5–6.8), expect reduced but measurable activity — adjust your assay buffer accordingly and include a pH-matched control. For standard enzymatic characterisation, 100 mM sodium acetate pH 5.5 with 2 mM DTT and 1 mM EDTA gives reproducible results. Always equilibrate the enzyme in assay buffer before commencing the reaction.

Can I use TPB recombinant Cathepsin V as a Western blot positive control for the matched anti-Cathepsin V antibody?

Yes. The TPB anti-Cathepsin V rabbit polyclonal antibody (SKU: RP-CathepsinV; see /anti-cathepsin-v-rabbit-polyclonal-antibody) was developed and validated in the same laboratory as this recombinant, making it a reliable positive-control pairing. Load 20–50 ng of recombinant Cathepsin V per lane on a 12–15% SDS-PAGE gel under reducing conditions. The heavy chain should appear at 24–28 kDa (with glycosylation). Use RP-CathepsinV at the manufacturer's recommended dilution (typically 1:500–1:2000 for Western blot). The HEK293 expression system preserves mammalian post-translational modifications, ensuring the epitope context is biologically relevant.

How much recombinant Cathepsin V should I load for a Western blot positive control, and what band should I expect?

Load 20–50 ng per lane as a starting point alongside your cell lysate samples; this amount typically produces a clear, non-saturated band with chemiluminescent or fluorescent detection systems. On a reducing 12% SDS-PAGE, the major band will be the mature heavy chain at ~24–28 kDa (HEK293 glycoforms shift the exact position slightly). A faint band near 5 kDa corresponding to the light chain may be visible with sensitive detection but can run off standard gels — use a 15–18% or Tricine gel if you want to capture it. Pair with RP-CathepsinV (SKU: RP-CathepsinV) for validated detection.

How should I store and handle recombinant Cathepsin V to maintain activity, and what is the shelf life?

Store at -20 °C in single-use aliquots immediately upon receipt. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — stabilises the protein during frozen storage. Avoid repeated freeze-thaw cycles; each cycle risks partial denaturation and loss of cysteine-protease activity at the active site. Aliquot to working volumes (typically 5–10 µg per tube) before first use. Under recommended conditions, activity is stable for at least 12 months. Before assay, thaw on ice, briefly centrifuge, and pre-reduce in assay buffer with 2–5 mM DTT for 10–15 minutes at 37 °C to fully activate the enzyme.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinV will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →